Dawson James Small Cap Growth Conference
October 19, 2017
The third annual Dawson James Small Cap Growth Conference features a full day of presentations from more than 30 companies in the health care, technology and consumer sectors. Following the presentations, the evening panel will be: The Convergence of A.I. and Healthcare – New Developments in Precision Medicine. Last year's event was attended by more than 250 of Dawson James' institutional, family office and high net worth clients. For more information visit www.DawsonJames.com
Acasti Pharma (ACST)
Acasti Pharma (NASDAQ: ACST) is a biopharmaceutical innovator advancing CaPre® (omega-3 phospholipid), a potentially best-in-class cardiovascular drug, for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population. The corporation's strategy is to initially develop and commercialize CaPre for the 3 million - 4 million patients in the U.S. with severe hypertriglyceridemia. Acasti Pharma is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit the company's website at www.acastipharma.com.
AmpliPhi BioSciences (APHB)
AmpliPhi BioSciences (NYSE: APHB) is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi's lead product candidates target multidrug-resistant S. aureus and Pseudomonas aeruginosa. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information, visit the company's website at www.ampliphibio.com.
Biocept (NASDAQ: BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The company leverages its proprietary liquid biopsy technology to provide physicians clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells and in circulating tumor DNA. With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For more information, visit the company's website at www.biocept.com.
BioSig Technologies (BSGM)
BioSig Technologies (OTC: BSGM) is a medical device company developing a proprietary technology platform designed to improve the $4+ billion electrophysiology (EP) marketplace. Led by a proven management team, BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market. The PURE EP System is a novel cardiac signal acquisition and display system engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. For more information, visit the company's website at www.biosigtech.com.
Cancer Genetics (CGIX)
Cancer Genetics (NASDAQ: CGIX) enables precision medicine in oncology through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the U.S., India and China. The company has established strong clinical research collaborations with multiple prestigious cancer centers. CGI offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the U.S. and have licensure from several states including New York State. For more information, visit the company's website at www.cancergenetics.com.
Catalyst Biosciences (CBIO)
Catalyst Biosciences (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, visit the company's website at www.catalystbiosciences.com.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) develops phospholipid drug conjugates designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on its proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information, visit the company's website at www.cellectar.com.
Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. Citius seeks to achieve leading market positions by providing therapeutic products that address unmet medical needs, using previously approved drugs with substantial safety and efficacy data, and reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, visit the company's website at www.citiuspharma.com.
ENDRA Life Sciences (NDRA)
ENDRA Life Sciences (NASDAQ: NDRA) develops enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA's next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") will enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI -- at a fraction of the cost, and at the point-of-care. For more information, visit the company's website at www.endrainc.com.
Finjan Holdings (FNJN)
Finjan Holdings (NASDAQ: FNJN) is a globally recognized leader in cybersecurity. Finjan's inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation. For more information, visit the company's website at www.finjan.com.
Heat Biologics (HTBX)
Heat Biologics (NASDAQ: HTBX) is a biopharmaceutical company developing immunotherapies to activate a patient's immune system against cancer using CD8+ "Killer" T-cells. The company's T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitor therapies and other immuno-modulators to increase effectiveness. Heat Biologics is currently enrolling patients in its phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). The company has numerous pre-clinical programs at various stages of development. For more information, visit the company's website at www.heatbio.com.
InspireMD (NYSE: NSPR) seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. For more information, visit the company's website at www.inspiremd.com.
Interpace (NASDAQ: IDXG) is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® for the diagnosis of thyroid cancer from thyroid nodules; and ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. For more information, visit the company's website at www.interpacediagnostics.com.
Matinas BioPharma (MTNB)
Matinas BioPharma (NYSE: MTNB) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology. For more information, visit the company's website at www.matinasbiopharma.com.
Meridian Waste Solutions (MRDN)
Meridian Waste Solutions (NASDAQ: MRDN) is focused on finding and implementing solutions to solid waste needs and challenges within the industry and for its customers. Meridian Waste's core business is centered on residential and commercial waste collection and disposal but it also includes a fundamental objective to seek rewarding environmental solutions through innovation. The company services over 113,000 residential, commercial, industrial and governmental customers. In addition to a fleet of commercial, residential and roll off trucks, the company operates four transfer stations, one recycling facility and three municipal solid waste landfills. For more information, visit the company's website at www.MWSinc.com.
Milestone Scientific (MLSS)
Milestone Scientific (NYSE: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information, visit the company's website at www.milestonescientific.com.
NanoVibronix (OTC: NAOV) is a medical device company focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company's groundbreaking technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and bacteria colonization, as well as providing pain relief. The devices can be administered at home, without the assistance of medical professionals. The company's products include PainShield® UroShield™ NG-Shield™ and WoundShield™. For more information, visit the company's website at www.nanovibronix.com.
Ohr Pharmaceutical (OHRP)
Ohr Pharmaceutical (NASDAQ: OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. For more information, visit the company's website at www.ohrpharmaceutical.com.
Onconova Therapeutics (ONTX)
Onconova Therapeutics (NASDAQ: ONTX) is a phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary phase 3 small molecule agent, which the company believes blocks cellular signaling by targeting RAS effector pathways. Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. For more information, visit the company's website at www.onconova.com.
Opiant Pharmaceuticals (OPNT)
Opiant Pharmaceuticals (NASDAQ: OPNT) is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company's partner, Adapt Pharma Operations Limited. For more information, visit the company's website at www.opiant.com.
Pareteum (NYSE: TEUM) is a technology company that seeks to connect "every person and everything." Organizations use Pareteum to energize their growth and profitability through cloud communication services and complete turnkey solutions featuring relevant content, applications, and connectivity worldwide. By harnessing the value of communications, Pareteum serves retail, enterprise and IoT customers. Pareteum currently has offices in New York, Sao Paulo, Madrid, Barcelona, Bahrain and the Netherlands. For more information, visit the company's website at www.pareteum.com.
Sensus Healthcare (SRTS)
Sensus Healthcare (NASDAQ: SRTS) is a medical device company committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit the company's website at www.sensushealthcare.com.
ShiftPixy (NASDAQ: PIXY) is a human capital management (HCM) services provider, revolutionizing employment in the gig economy by delivering a next-gen platform for workforce management that helps shift-based employers navigate regulatory mandates, minimize administrative burdens, and connects them with a ready-for-hire workforce. ShiftPixy adds a needed layer for addressing compliance and continued demands for equitable employment practices in the growing Gig Economy. ShiftPixy's complete HCM ecosystem manages regulatory requirements and compliance in such required areas as paid time off (PTO) laws, insurance and workers' compensation, minimum wage increases, and the Affordable Care Act (ACA) compliance. For more information, visit the company's website at www.shiftpixy.com.
Sigma Labs (SGLB)
Sigma Labs (NASDAQ: SGLB) is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information, visit the company's website at www.sigmalabsinc.com.
Skyline Medical (SKLN)
Skyline Medical (NASDAQ: SKLN) produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship. For more information, visit the company's website at www.skylinemedical.com.
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, a first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201). For more information, visit the company's website at www.soligenix.com.
Sonoma Pharmaceuticals (SNOA)
Sonoma Pharmaceuticals (NASDAQ: SNOA) is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. For more information, visit the company's website at www.sonomapharma.com.
Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals (NASDAQ:TNXP) is developing innovative pharmaceutical and biological products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine. For more information, visit the company's website at www.tonixpharma.com.
Westwater Resources (WWR)
Westwater Resources (NASDAQ: WWR) (formerly known as Uranium Resources, Inc.) is focused on expanding its energy metals strategy, which includes developing its new lithium business while maintaining optionality in the case of a future rising uranium price. The company is pursuing lithium exploration and development projects that leverage its broad base of hydrogeological, well field engineering and hydrometallurgical expertise in the Western United States. Since the second half of 2016, the company has identified and acquired three high potential lithium brine exploration projects. For more information, visit the company's website at www.westwaterresources.net.
VolitionRX Ltd. (VNRX)
VolitionRX Ltd. (NYSE: VNRX) Volition (NYSE: VNRX) is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Volition's research and development activities are centered in Belgium, with additional offices in London, Texas and Singapore. For more information, visit the company's website at www.volitionrx.com.